Scarica l'app Stockscreener
72.77
1.80%
1.29
Dopo l'orario di chiusura:
72.77
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years? - Yahoo Finance
BlackRock, Inc. Reduces Stake in Corcept Therapeutics Inc - GuruFocus
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? - Nasdaq
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS - GuruFocus
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL - Business Wire
3 Healthcare Stocks That Concern Us - Yahoo Finance
Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today - Benzinga
March sees multiple phase III successes, boosting Corcept and Mineralys - BioWorld MedTech
Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - MSN
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSEL - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 | CORT Stock News - GuruFocus
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 - Business Wire
Corcept: Maintaining Strong Buy Even After Q4 Revenue And Earnings Miss - Seeking Alpha
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus
Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com
Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - Yahoo Finance
SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com
$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha
Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada
Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com
3 Biopharmaceutical Stocks Bucking the Sell-Off - MarketBeat
Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo
Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire
Corcept begins trial for ovarian cancer treatment By Investing.com - Investing.com India
How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga
Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World
Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia
Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK
Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada
Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia
Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada
Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com
Corcept therapeutics president sells shares worth $10.1 million - Investing.com
Corcept therapeutics officer sells $20.2 million in stock - Investing.com
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance
Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN
Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada
Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus
Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus
U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's
Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus
Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga
Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - TradingView
Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Nasdaq
Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):